- Conditions
- Head and Neck Cancer
- Interventions
- biologic sample preservation procedure, medical chart review
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2050
- U.S. locations
- 4
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 776
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
- Conditions
- Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
- Interventions
- FoundationOne Liquid CDx
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 12 Months to 50 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal Tumors (PNETs), Germ Cell Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma, Wilms Tumor, Renal Cell Carcinoma, Malignant Rhabdoid Tumor, Clear Cell Sarcoma, Liver Tumors
- Interventions
- Guided Therapy
- Device
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 13 Months to 21 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
- Conditions
- Ependymoma, Glioblastoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges
- Interventions
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Brain Tumor, Pediatric, Medulloblastoma, Pediatric
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
- Interventions
- DCR-MYC
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Interventions
- 68Ga-DOTATOC PET/CT
- Drug
- Lead sponsor
- Sue O'Dorisio
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Neuroblastoma
- Interventions
- buthionine sulfoximine, melphalan
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 0 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 1 more
- Conditions
- Neuroblastoma
- Interventions
- Injection of allogeneic neuroblastoma cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2016
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma
- Interventions
- Natural Killer Cells, Temozolomide, Irinotecan, Dinutuximab, Sargramostim
- Biological · Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 29 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Recurrent Childhood Medulloblastoma
- Interventions
- vismodegib, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 9
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more
- Conditions
- Neuroblastoma, High-Risk
- Interventions
- cyclophosphamide, NK cells, hu3F8, rIL-2
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neuroblastoma
- Interventions
- DFMO
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 19 more
- Conditions
- Neuroblastoma
- Interventions
- β-glucan, GM-CSF, OPT-821
- Dietary Supplement · Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 286 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed Neuroblastoma, Metastatic Pheochromocytoma
- Interventions
- 131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion
- Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- 90Y-DOTA-tyr3-OCTREOTIDE
- Radiation
- Lead sponsor
- O'Dorisio, M S
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Tumor-associated Hyperinsulinism (Tumor HI)
- Interventions
- Ersodetug (9 mg/kg) + SOC
- Drug
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Interventions
- LEQ506
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Central Nervous System/Leptomeningeal Neoplasms
- Interventions
- 131I-omburtamab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cancer
- Interventions
- caspofungin acetate, liposomal amphotericin B
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
- Interventions
- deferasirox
- Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
- Interventions
- Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Medulloblastoma
- Interventions
- Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 59 Months
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2035
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more